Pfizer CEO says coronavirus vaccine data will roll in fast enough for results late October 20% of clinicians considering leaving primary care in light of COVID-19-linked financial challenges: survey Sanofi, GSK start COVID-19 vaccine trial, eye H1 2021 approval Steroids can save the lives of very ill COVID-19 patients, new studies confirm Biopharma roundup: U.S. won’t join WHO global vaccine initiative Bloomberg commits $100M to historically Black medical schools amid COVID-19 pressures NIH's COVID-19 diagnostic competition awards $129M to boost 9 more test makers Biotech CEOs pen standards for coronavirus trials, data disclosures amid FDA reputation crisis MedPAC: For-profit systems fare better than non-profits in weathering COVID-19 cash crisis AstraZeneca signs on Albany Molecular to help boost COVID-19 shot production Featured Story | By Eric Sagonowsky Pfizer CEO Albert Bourla said the company has enrolled about 23,000 people for its phase 3 COVID-19 vaccine trial, and the way things are going, initial results should be ready in late October. If the numbers are positive, the company would be ready to ask FDA for an authorization immediately. read more |
| |
|---|
|
Top Stories By Tina Reed The primary care industry is contracting in the face of financial challenges from the COVID-19 pandemic, according to a new survey from the Larry A. Green Center and Primary Care Collaborative. read more By Nick Paul Taylor Sanofi and GlaxoSmithKline have moved their adjuvanted protein-based COVID-19 vaccine into the clinic, setting them on a path they expect to lead to a filing for approval in the first half of next year. read more By Angus Liu When researchers in the U.K. said in June that the low-cost corticosteroid dexamethasone could reduce death rates in critically ill COVID-19 patients, clinicians still had doubts about whether to change their treatment practice without full data. But a new meta-analysis examining clinical trials in different parts of the world, whose findings were simultaneously published on Wednesday in JAMA, will likely change that. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Albany Molecular will perform fill-finish work on "millions" of AstraZeneca shots. The NIH selected nine more test makers to advance through its COVID diagnostics competition. The U.S. won't join WHO's COVAX, a White House spokesperson said. California could make its own generic drugs, plus many U.S. hospitals are hesitant to treat COVID patients with plasma. read more By Tina Reed The funds from Bloomberg Philanthropies will go toward "significantly reducing the debt burden" of about 800 students, many who are experiencing increased financial pressure amid COVID-19. read more By Conor Hale The National Institutes of Health has picked nine additional test manufacturers to advance through its “Shark Tank”-like COVID-19 diagnostics competition—alongside $129.3 million in new funding to help scale up the production of both point-of-care screening tests and high-throughput laboratory assays. read more By Eric Sagonowsky Amid doubts about the FDA’s decision-making process during the pandemic, biotech CEOs on the front lines of research are laying out their approach and asking “all parties” involved in the process to adhere to high scientific standards. read more By Robert King A new analysis from MedPAC found for-profit hospital systems have done a better job of weathering the COVID-19 financial crisis than their non-profit counterparts. read more By Kyle Blankenship British drugmaker AstraZeneca is on a mission to lock in as many manufacturing partners as possible to support a planned global rollout for its COVID-19 vaccine frontrunner. A New York CDMO has now jumped on board, and it will commit its Southwestern facility to help pick up the slack. read more |
